T. Rowe Price Associates’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $23.5M | Buy |
|
|||||
|
2025
Q2 | $20M | Buy |
|
|||||
|
2025
Q1 | $10.8M | Buy |
|
|||||
|
2024
Q4 | $11.4M | Sell |
|
|||||
|
2024
Q3 | $10.2M | Sell |
|
|||||
|
2024
Q2 | $15M | Sell |
|
|||||
|
2024
Q1 | $74M | Sell |
|
|||||
|
2023
Q4 | $162M | Sell |
|
|||||
|
2023
Q3 | $109M | Sell |
|
|||||
|
2023
Q2 | $144M | Buy |
|
|||||
|
2023
Q1 | $85.6M | Buy |
|
|||||
|
2022
Q4 | $68.1M | Sell |
|
|||||
|
2022
Q3 | $80M | Buy |
|
|||||
|
2022
Q2 | $66.1M | Sell |
|
|||||
|
2022
Q1 | $121M | Sell |
|
|||||
|
2021
Q4 | $221M | Buy |
|
|||||
|
2021
Q3 | $157M | Sell |
|
|||||
|
2021
Q2 | $249M | Buy |
|
|||||
|
2021
Q1 | $216M | Buy |
|
|||||
|
2020
Q4 | $421M | Sell |
|
|||||
|
2020
Q3 | $435M | Sell |
|
|||||
|
2020
Q2 | $550M | Sell |
|
|||||
|
2020
Q1 | $500M | Sell |
|
|||||
|
2019
Q4 | $566M | Buy |
|
|||||
|
2019
Q3 | $366M | Buy |
|
|||||
|
2019
Q2 | $201M | Buy |
|
|||||
|
2019
Q1 | $198M | Buy |
|
|||||
|
2018
Q4 | $111M | Buy |
|
|||||
|
2018
Q3 | $66.2M | Buy |
|
|||||
|
2018
Q2 | $7.95M | Sell |
|
|||||
|
2018
Q1 | $17.7M | Sell |
|
|||||
|
2017
Q4 | $24.5M | Sell |
|
|||||
|
2017
Q3 | $78.6M | Sell |
|
|||||
|
2017
Q2 | $96.5M | Sell |
|
|||||
|
2017
Q1 | $158M | Sell |
|
|||||
|
2016
Q4 | $163M | Sell |
|
|||||
|
2016
Q3 | $214M | Sell |
|
|||||
|
2016
Q2 | $231M | Sell |
|
|||||
|
2016
Q1 | $223M | Buy |
|
|||||
|
2015
Q4 | $199M | Buy |
|
|||||
|
2015
Q3 | $185M | Sell |
|
|||||
|
2015
Q2 | $236M | Sell |
|
|||||
|
2015
Q1 | $197M | Sell |
|
|||||
|
2014
Q4 | $198M | Sell |
|
|||||
|
2014
Q3 | $162M | Buy |
|
|||||
|
2014
Q2 | $135M | Buy |
|
|||||
|
2014
Q1 | $67.7M | Buy |
|
|||||
|
2013
Q4 | $64.9M | Buy |
|
|||||
|
2013
Q3 | $51.3M | Buy |
|
|||||
|
2013
Q2 | $25.1M | Buy |
|